Delayed lung injury on the nonsurgical side increases mortality in patients after lung cancer surgery: a retrospective cohort study.

Background: The incidence of pulmonary complications following lung cancer surgery has declined recently; however, postoperative acute lung injury (PALI) is still common. The present study aimed to assess the prognosis of PALI after lung cancer surgery on different injury sides, describe its clinical characteristics and identify risk factors. Methods: This was a monocenter retrospective study conducted in a university surgical intensive care unit (SICU). Patients requiring respiratory support with severe hypoxemia after lung cancer surgery were included. Patients were categorized based on the radiographic assessment of lung edema (RALE) score ratio, which calculates the severity of surgical/nonsurgical side of lung injury [RRALE; RALE score of the surgical side (RALES) divided by RALE score of nonsurgical side (RALENS)], into two groups: the nonsurgical-side lung injury group (RRALE <1) and others (RRALE ≥1). The primary outcome was 90-day mortality, and secondary outcomes included in-hospital 28-day mortality, total intensive care unit (ICU) length of stay (LOS), hospital LOS and 6-month survival. Results: Sixteen patients were enrolled in this study. Nine patients were included in the RRALE <1 group and seven patients were included in the RRALE ≥1 group. At 90 days, six patients in the RRALE <1 group had died, whereas none died in the RRALE ≥1 group (P=0.01). No significant difference was observed in in-hospital 28-day all-cause mortality (P=0.48) or ICU or hospital LOS (P=0.34 and P=0.36, respectively) between the two groups. Survival at 6 months was significantly lower in the RRALE <1 group (33.33%) than in the RRALE ≥1 group (100.00%) (P=0.009). Conclusions: Patients with severe lung injury on the nonsurgical side after lung cancer surgery had high 90-day mortality rates. Large prospective studies and accurate monitoring data are needed in the future to identify the risk factors and therapy for such lung injury.

Cerebral Blood Flow Alterations in Sepsis-Associated Encephalopathy: A Prospective Observational Study.

BACKGROUND: The timely recognition of sepsis-associated encephalopathy (SAE) remains a challenge. This study aimed to observe the CBF changes via TCD during sepsis and explore their possible predictive value in SAE. METHODS: In this prospective observational study, septic patients were enrolled and classified according to the diagnosis of SAE into two groups: SAE group and non-SAE group. Then SAE patients were further divided into subgroup A (the type with agitation) and subgroup B (the type with depressed consciousness) based on their clinical manifestations. The clinical profiles and TCD parameters within 24 hours of onset were compared between groups and subgroups. RESULTS: Exactly 198 septic patients were enrolled including 65 patients in SAE group (36 male/29 female with a median age of 70) and 133 patients in non-SAE group (75 male/58 female with a median age of 67). Significant elevated peak-systolic velocity (VS; 107 [69-138] cm/s vs 85 [69-101] cm/s, P = .002) of the left middle cerebral artery (MCA) and pulsatility index (PI; left: 0.99 [0.81-1.34] vs 0.89 [0.76-1.00], P < .001; right: 0.99 [0.77-1.21] vs 0.88 [0.78-1.03], P = .007) of bilateral MCAs were found in SAE group compared with non-SAE group. In subgroup analysis, subgroup A (the type with agitation) showed significantly increased VS/VM/VD and lower PI/RI of bilateral MCAs compared with subgroup B (the type with depressed consciousness). The cerebral blood flow volume of subgroup A were obviously higher than subgroup B [858.7 (729.1,876.9) mL/s vs 380.9 (373.3,447.4) mL/s, P < .001]. CONCLUSIONS: This study confirmed the abnormal CBF among SAE and found different types of CBF alterations were related to different clinical features. VS and PI might help clinicians to early identify different types of SAE.

Comparative study of high flow nasal catheter device and noninvasive positive pressure ventilation for sequential treatment in sepsis patients after weaning from mechanical ventilation in intensive care unit.

BACKGROUND: The hypoxemia condition after mechanical ventilation (MV) weaning is not rare among sepsis patients, so we compared the efficacy in two different intervention groups: high-flow nasal cannula device group and non-invasive positive pressure ventilation (NPPV) group. METHODS: This is a retrospective cohort study. Participants were patients with sepsis receiving high-flow nasal catheter (HFNC) device or NPPV within 24 hours after weaning from MV. The primary outcome was tracheal re-intubation within 72 hours after extubation. Secondary outcomes included: oxygenation index, complication rate, patient comfort evaluation, HFNC/NPPV treatment time, ICU length of stay (LOS), ICU mortality, and in-hospital 28-day mortality. RESULTS: A total of 283 patients were included in the study with 167 in the HFNC group and 116 in the NPPV group. The re-intubation rates after extubation in both groups were respectively 4.2% and 5.2% without significant difference. Patients in the HFNC group experienced lower incidence of delirium, reflux aspiration, facial pressure ulcer and other complications, and higher score of patients comfort than that in the NPPV group. There was no significant difference in ICU LOS, ICU mortality and in-hospital 28-day mortality between the two groups. CONCLUSIONS: HFNC and NPPV have similar efficacy in the sequential treatment of sepsis patients after weaning from MV. Compared with NPPV, those extubated to HFNC had lower rate of complications such as reflux aspiration and facial pressure ulcers. The patients extubation to HFNC is more comfortable (and associated with less delirium) than to NPPV.

Ulinastatin ameliorates LPS­induced pulmonary inflammation and injury by blocking the MAPK/NF­κB signaling pathways in rats.

Ulinastatin, a urinary trypsin inhibitor (UTI) is commonly used to treat patients with acute inflammatory disease. However, the underlying mechanisms of its anti­inflammatory effect in acute lung injury (ALI) are not fully understood. The present study aimed to investigate the protective effect of UTI and explore its potential mechanisms by using a rat model of lipopolysaccharide (LPS)­induced ALI. Rats were treated with 5 mg/kg LPS by intratracheal instillation. The histological changes in LPS­induced ALI was evaluated using hematoxylin and eosin staining and the myeloperoxidase (MPO) activity was determined using ELISA. The wet/dry ratio (W/D ratio) of the lungs was used to assess the severity of pulmonary edema and Evans blue dye was used to evaluate the severity of lung vascular leakage. The results demonstrated that LPS administration induced histological changes and significantly increased the lung W/D ratio, MPO activity and Evans blue dye extravasation compared with the control group. However, treatment with UTI attenuated LPS­induced ALI in rats by modifying histological changes and reducing the lung W/D ratio, MPO activity and Evans blue dye extravasation. In addition, LPS induced the secretion of numerous pro­inflammatory cytokines in bronchoalveolar lavage fluid (BALF), including tumor necrosis factor­α, interleukin (IL)­6, IL­1ß and interferon­Î³; however, these cytokines were strongly reduced following treatment with UTI. In addition, UTI was able to reduce cellular counts in BALF, including neutrophils and leukocytes. Western blotting demonstrated that UTI significantly blocked the LPS­stimulated MAPK and NF­κB signaling pathways. The results of the present study indicated that UTI could exert an anti­inflammatory effect on LPS­induced ALI by inhibiting the MAPK and NF­κB signaling pathways, which suggested that UTI may be considered as an effective drug in the treatment of ALI.

Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: A randomized controlled trial.

BACKGROUND: The methodology of thromboprophylaxis post minimally invasive esophagectomy (MIE) is unclear. Thus, we compared the efficacy and safety of fondaparinux and nadroparin on the prophylaxis of venous thromboembolism (VTE) after MIE. MATERIALS AND METHODS: We conducted a randomized, double-blind, treatment-controlled study. Consecutive patients undergoing MIE randomly received a single dose of either nadroparin 2850 AxaIU (Group H) or fondaparinux 2.5 mg (Group F) daily. We used ultrasonography to identify deep vein thrombosis (DVT) on postoperative day 7. The coagulation status was examined using thromboelastography (TEG) prior to and at 0, 24, 48, and 72 h after the operation. Bleeding events were recorded during anticoagulation therapy and analysis was performed on an intention-to-treat basis. RESULTS: We randomly assigned the patients to Group H (n = 57) or Group F (n = 59). Symptomatic or asymptomatic DVT was identified in seven patients in Group H and one patient in Group F (12.28% vs. 1.69%, p = 0.031). Pulmonary embolism developed in one patient in Group H, and the VTE incidence was significantly lower in Group F than Group H (1.69% vs. 14.04%, RR: 0.121, 95% CI: 0.016-0.935, p = 0.016). TEG analysis showed a more inhibited coagulation profile of Group F compared with Group H reflected by the significantly prolonged R time at 48 h and 72 h after operation (6.8 ±â€¯2.2 min vs. 8.4 ±â€¯2.7 min, p = 0.005; 7.1 ±â€¯1.6 min vs. 9.2 ±â€¯3.7 min, p = 0.002). Bleeding events were not recorded in either group. CONCLUSIONS: Fondaparinux could provide similar efficacy and safety in postoperative thromboprophylaxis following MIE compared with nadroparin.

The efficacy of parenteral fish oil in critical illness patients with sepsis: a prospective, non-randomized, observational study.

BACKGROUND AND OBJECTIVES: To investigate the clinical outcomes in septic patients receiving parenteral fish oil. METHODS AND STUDY DESIGN: A prospective, non-randomized, observational clinical study was carried out in 112 patients with sepsis from March, 2013 to May, 2015 in the surgical intensive care unit (SICU) of a tertiaryreferral hospital. The patients were put into one of two groups; either the control or the study group. Patients received the standard treatment of sepsis based on guidelines in the control group. In the study group, patients received parenteral nutrition (PN) containing fish oil. The Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, the length of ICU and hospital stay, duration of mechanical ventilation, mortality, and readmission into the ICU were recorded. Tumor necrosis factor (TNF)-α and procalcitonin (PCT) levels were also evaluated. RESULTS: The study group showed a significant reduction for all-cause mortality (20.0% vs 10.0% in study and control groups, p=0.034) and APACHE II score on day 5 (p=0.015), day 7 (p=0.036) and day out of SICU (p=0.045) compared with the control group. The study group tended to show a shortened length of stay in the ICU compared to the control group. However, TNF-α and PCT level, 28 d mortality, the length of hospital stay and the duration of mechanical ventilation did not show statistical differences between the two groups. There were no drug-related adverse effects shown during the study. CONCLUSIONS: PN with fish oil is probably safe and may improve clinical outcome in critical ill patients with sepsis.

Comparison of Percutaneous Dilatational Tracheostomy Guided by Ultrasound and Bronchoscopy in Critically Ill Obese Patients.

OBJECTIVES: This study aimed to compare the efficacy and safety of percutaneous dilatational tracheostomy (PDT) with ultrasound (US) or bronchoscopic guidance for critically ill patients, notably obese patients. METHODS: This work was a retrospective study. The study included mechanically ventilated patients who underwent PDT from August 2013 to July 2015 in the Department of Critical Care Medicine of Zhongshan Hospital. The patients were classified according to the different guidance methods during tracheotomy and their body mass index in the following 4 groups: normal bronchoscopy group, normal US group, obese bronchoscopy group, and obese US group. The parameters, including operation time, number of punctures, intraoperative and postoperative complications, duration of the intensive care unit stay, hospitalization time, and mortality, were recorded and compared between groups. RESULTS: Compared with the obese bronchoscopy group, the obese US group had a significantly shorter PDT operation time (mean ± SD, 12.8 ± 4.8 versus 16.2 ± 4.4 minutes; P = .026), fewer punctures (P = .011), and a lesser amount of intraoperative hemorrhage (12.1 ± 4.6 versus 16.8 ± 4.3 mL; P = .009). There were no significant differences in these parameters between the normal US and normal bronchoscopy groups. CONCLUSIONS: Ultrasound-guided PDT significantly reduced the number of punctures and the operation time compared with bronchoscopy-guided PDT, and it decreased intraoperative hemorrhage in critically ill obese patients. Percutaneous dilatational tracheostomy with US guidance was a faster, safer, and more accurate method of airway management.

Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial.

BACKGROUND: Venous thromboembolism (VTE) remained common complication following surgical resection of esophageal cancer. In this prospective randomized double-blind placebo-controlled trial (NCT01267305), we aim to compare the safety and efficacy between low molecular weight heparin (LMWH) once-daily (QD) and twice-daily (BID) for the prophylaxis of VTE following esophagectomy. METHODS: During August 2012 to July 2013, patients underwent esophagectomy were randomly assigned to nadroparin calcium QD (4,100 AxaIU qd + placebo qd, group QD), or nadroparin calcium BID (4,100 AxaIU q12h, group BID) in the prophylaxis of VTE. All patients received thrombelastography (TEG) before and 0/24/48/72 hours after operation. Daily vascular ultrasound of lower extremities was followed during the first 7 postoperative days to confirm the suspected deep venous thrombosis (DVT). Cumulatively postoperative chest drainage at 72 hours after the surgery was collected to identify the difference in volume and red blood cell (RBC) counts between the two groups. Any bleeding events and thromboembolic events were also documented. RESULTS: A total of 117 patients were enrolled in this study, and 111 eligible patients were randomly assigned (group QD: 55 patients; group BID: 56 patients). Patients' clinical features were close between the two groups. TEG analysis [R time, K time, alpha angel and maximum amplitude (MA)] before and instantly after operation showed nearly identical results. However, compared with group QD, all TEG measurements of 24/48/72 hours postoperatively showed significantly prolonged R time and K time, and decreased alpha angel in group BID. In ultrasound follow-ups, a total of four cases of DVT (four cases in group QD and no case in group BID) were found in this cohort (7.27% versus 0%, P=0.046), and one case of pulmonary embolism (PE) (in group QD) was observed. The incidence of VTE was lower in group BID (9.09% versus 0%, P=0.032). At 72 hours after surgery, the cumulative volume of chest drainage were close between these two groups (1,001.39±424.58 versus 1,133.61±513.93 mL, P=0.406). RBC counts in chest drainage were also identical between two groups [(2.56±1.98)×10(5) versus (2.71±4.67)×10(5), P=0.61]. No patient died due to VTE or bleeding events. CONCLUSIONS: For the prophylaxis of VTE, BID LMWH provided more potent efficacy and equal safety when compared to QD LMWH in patients undergoing selective esophagectomy. Further study based on larger population is required to confirm these findings.

[Effect of Xuebijing injection on rabbits ischemia/reperfusion injury induced by femoral arterial disease].

OBJECTIVE: To investigate the changes in serum malondialdehyde (MDA), interleukin-1ß (IL-1ß), tumor necrosis factor-α (TNF-α), aspartate aminotransferase (AST) and creatinine (Cr) after the reproduction of ischemia/reperfusion (I/R) injury model, and the protective effects of liver and kidney with Xuebijing injection on acute I/R injury in rabbits. METHODS: Sixty rabbits were divided into six groups with a random number: A, normal group; B, sham operated group; C, model group, and D, E, F groups (Xuebijing low, middle, high dosage treatment groups). I/R injury model was reproduced (after a 4-hour ischemia, the femoral vessels were reperfusion). Physiological saline (2 ml/kg) or 0.33, 0.66 and 1.32 g/kg Xuebijing injection were given at 0, 12, 36, 60 hours after operation via ear vein. MDA, IL-1ß, TNF-α, AST and Cr were determined at 6, 12, 24 and 72 hours after reperfusion in each group. RESULTS: MDA, IL-1ß, TNF-α at different time points, AST and Cr at 72 hours after reperfusion in C group were significantly higher than those in A group and B group. Compared with the C group, the above indexes were gradually decreased with does-dependence, the values of MDA (µmol/L), IL-1ß (ng/L) and TNF-α (µg/L) in serum of group F at 6, 12, 24 and 72 hours after reperfusion were significantly lower (MDA: 9.74 ± 3.71 vs. 12.35 ± 4.64, 11.26 ± 4.14 vs. 12.82 ± 3.85, 9.72 ± 2.25 vs. 13.30 ± 2.83, 9.12 ± 2.72 vs. 13.10 ± 2.72; IL-1ß: 83.49 ± 12.79 vs. 100.09 ± 17.53, 85.10 ± 11.75 vs. 102.64 ± 19.64, 75.97 ± 11.29 vs. 99.24 ± 14.62, 81.96 ± 14.81 vs. 99.59 ± 12.05; TNF-α: 8.95 ± 1.13 vs. 9.94 ± 1.29, 8.79 ± 1.80 vs. 9.56 ± 0.89, 8.27 ± 1.83 vs. 9.51 ± 1.32, 7.23 ± 1.39 vs. 9.23 ± 1.05, P < 0.05 or P < 0.01). The values of AST(U/L) and Cr (µmol/L) in serum of groups D, E and F at 24 hours and 72 hours after reperfusion were significantly lower (AST 24 hours: 24.00 ± 1.27, 23.80 ± 1.11, 22.90 ± 1.65 vs. 39.50 ± 1.73, 72 hours: 32.15 ± 1.95, 32.90 ± 1.77, 32.25 ± 2.25 vs. 52.86 ± 2.43; Cr 24 hours: 273.78 ± 17.04, 267.07 ± 19.59, 265.25 ± 15.59 vs. 347.60 ± 18.83, 72 hours: 437.38 ± 18.48, 343.77 ± 16.79, 351.48 ± 20.22 vs. 437.50 ± 19.86, all P < 0.01). CONCLUSIONS: It is demonstrated that I/R injury could dramatically lead to systemic inflammatory response and oxygen free radical injury. Xuebijing injection in higher dosage can reduce the systemic inflammatory response significantly, and also MDA level in serum. Xuebijing injection in low dosage, middle dosage and high dosage can produce protective effects against the damages to liver and kidney function.